Generic Name and Formulations:
Dinoprostone 10mg; controlled-release vaginal insert w. retrieval system.
Indications for CERVIDIL:
Cervical ripening in patients at or near term when there is an indication for labor induction.
Fetal distress where delivery is not imminent. Unexplained vaginal bleeding. Presence or suspicion of cephalopelvic disproportion. Where oxytocics or prolonged uterine contractions are inappropriate, including previous cesarean section, major uterine surgery. Multipara with ≥6 previous term pregnancies. Concomitant oxytocics. Remove insert if uterine hyperstimulation, labor, sustained uterine contractions, or other fetal/maternal adverse reactions occur and prior to amniotomy.
For hospital use when appropriate obstetric care is present. Ruptured membranes. Non-vertex, non-singleton presentation. Previous uterine hypertony. Glaucoma. History of childhood asthma. Monitor uterine activity, fetal status, cervical dilatation/effacement. Pregnancy (Cat.C).
Potentiates oxytocics; delay administration of oxytocics at least 30 minutes after removal of insert.
Uterine hyperstimulation, fetal distress.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks